Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 503 of 6351
-
Can a blood test find the right drug dose faster for sickle cell?
Disease control Recruiting nowThe goal of this study is to evaluate if patients with sickle cell disease can achieve a maximum tolerate dose of hydroxuyrea (HU) over a period of 12 months faster with pharmacokinetic testing than the standard of care bloodwork follow-up. Pharmacokinetic test is used to evaluat…
Phase 2/3 • Sponsor: Yves Pastore • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New cocktail aims to snuff out residual AML before it returns
Disease control Recruiting nowThe purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This resea…
Phase 1/2 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Eye tests may predict Alzheimer's before symptoms show
Diagnosis Recruiting nowAlzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be asses…
Phase 2 • Sponsor: University Hospital, Toulouse • Aim: Diagnosis
Last updated Jul 19, 2026 00:00 UTC
-
New hope for tough prostate cancer: HRS-4357 faces off against standard care in major trial
Disease control Recruiting nowThis study is a randomized, open-label, controlled, multicenter phase III clinical trial, which plans to randomly enroll 370 subjects with advanced metastatic castration-resistant prostate cancer (mCRPC). The efficacy of HRS-4357 versus novel androgen receptor pathway inhibitors …
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
AI-Designed vaccine takes on lung cancer in new trial
Disease control By invitation onlyMicrolyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care chemo-immunotherapy, with treatment tailored by histolo…
Early phase 1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Blood test boosts liver cancer detection in High-Risk patients
Diagnosis By invitation onlyHCC surveillance is currently limited by underutilization and the suboptimal performance of AFP. This prospective, single-arm study investigates whether the GAAD score (Gender, Age, AFP, and PIVKA-II) enhances HCC detection when added to standard-of-care surveillance. High-risk …
Sponsor: Siriraj Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New catheter aims to clear stroke clots faster
Disease control Recruiting nowThe purpose of this study is to assess the safety and the effectiveness of the Adaptive Tip Catheter (ATC) used as a first line direct aspiration thrombectomy technique for patients suffering of an acute ischemic stroke.
Sponsor: Neuravi Limited • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New inhaled drug aims to fight deadly lung scarring
Disease control Recruiting nowRationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by prog…
Phase 2 • Sponsor: Rein Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Immune cells engineered to attack lung cancer show promise in early trial
Disease control Recruiting nowThis is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors co-express at least two of the following antigens:…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Supercharged immune cells take on pancreatic cancer in new trial
Disease control Recruiting nowThis example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants are assig…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of genetically engineered cells (CD83 chimeric antigen receptor \[CAR\] T cells) in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or has not responde…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-targ…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1,TNBC cases mesothelin),…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells take aim at Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo attack on aggressive breast cancer brain tumors shows promise in early trial
Disease control Recruiting nowThis is an open-label, prospective, single-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with triple-negative breast cancer and brain metastases…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a High-Fat diet and therapy tame seizures in rare childhood epilepsy?
Disease control CompletedThis study evaluated the effects of medical ketogenic diet therapy combined with occupational therapy in children with ARX-related epilepsy. Twenty children were included. Ten children receiving a ketogenic diet formed the experimental group, and ten children not receiving a keto…
Sponsor: Uskudar University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a dengue vaccine be both Cost-Effective and trusted? a thai study investigates
Knowledge-focused OngoingStudy 1: Cost-effectiveness of TAK-003 Dengue Vaccination in Thailand This study aims to evaluate the cost-effectiveness of introducing the live-attenuated tetravalent dengue vaccine (TAK-003) into Thailand's national immunization program. The study will compare routine vaccinat…
Sponsor: Mahidol University • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Exercise as medicine? a new trial tests a Drug-Free fix for period pain
Symptom relief Completed\*\*Trial Summary\*\* Primary dysmenorrhea is a common condition among young women that can significantly impair daily functioning and health-related quality of life. This single-center randomized controlled trial evaluated the effectiveness of a 12-week structured physiotherapy…
Sponsor: Muhammad Nawaz Sharif University of Agriculture Multan • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Could live music tune the brain to ease Alzheimer's anxiety?
Symptom relief Recruiting nowThis study examines whether Clinically Designed Improvisatory Music (CDIM) can reduce anxiety in people living with Alzheimer's disease and anxiety (AD-A), and whether it can also lessen caregiver burden. CDIM is a live, receptive music-based intervention that uses slow tempi, si…
Sponsor: Northwestern University • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC